Kymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform

Mar 12, 2020•over 5 years ago

Amount Raised

$102 Million

Round Type

series c

Cambridge

Description

Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, today announced the closing of a $102 million Series C financing. The round was led by Biotechnology Value Fund (BVF) and Redmile Group with participation from Wellington Management Company, Bain Capital Life Sciences, funds managed by Janus Henderson Investors and BlackRock, Rock Springs Capital and a large US-based, healthcare-focused fund. Existing investors also participated in the round.

Company Information

Company

Kymera Therapeutics

Location

Cambridge, Maryland, United States

About

Kymera Therapeutics is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Powered by Pegasus™, a game-changing integrated degradation platform, Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. For more information visit, www.kymeratx.com.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Kymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Related People

Company Information